DGAP-News

RedHill Biopharma Announces YELIVA(R) (ABC294640) Abstract Presentation at the 2017 Cholangiocarcinoma Foundation Annual Conference

DGAP-News: RedHill Biopharma Ltd. / Key word(s): Conference
RedHill Biopharma Announces YELIVA(R) (ABC294640) Abstract Presentation at
the 2017 Cholangiocarcinoma Foundation Annual Conference

11.01.2017 / 09:19
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

RedHill Biopharma Announces YELIVA(R) (ABC294640) Abstract Presentation at
the 2017 Cholangiocarcinoma Foundation Annual Conference

- The abstract, to be presented at the upcoming 2017 Cholangiocarcinoma
Foundation Annual Conference, describes positive findings from non-
clinical studies and the Phase I clinical study with YELIVA(R)
(ABC294640), suggesting that YELIVA(R) may be an effective drug for the
treatment of cholangiocarcinoma

- A Phase I study with YELIVA(R) in patients with advanced solid tumors
successfully met its primary and secondary endpoints

- Of the three cholangiocarcinoma patients in the Phase I study, one
patient had a sustained partial response (Overall Survival (OS) = 20.3
months) and the other two had stable disease (OS = 17.6 and 16.3
months)

- YELIVA(R) is a proprietary, first-in-class, orally-administered
sphingosine kinase-2 (SK2) selective inhibitor, with anti-cancer and
anti-inflammatory activities

- RedHill is pursuing several Phase I/II clinical studies with YELIVA(R)
in the U.S., targeting multiple oncology and inflammatory indications,
some of which are supported by National Cancer Institute (NCI) grants
awarded to Apogee Biotechnology and U.S. universities

TEL-AVIV, Israel, January 11, 2017 RedHill Biopharma Ltd. (NASDAQ: RDHL)
(TASE: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical
company primarily focused on the development and commercialization of late
clinical-stage, proprietary, orally-administered, small molecule drugs for
gastrointestinal and inflammatory diseases and cancer, announced the
presentation of an abstract relating to YELIVA(R), the Company's
proprietary, first-in-class, orally-administered sphingosine kinase-2 (SK2)
selective inhibitor, at the 2017 Cholangiocarcinoma Foundation Annual
Conference, on February 2, 2017, in Salt Lake City, UT.

The abstract, entitled 'Targeting Sphingosine Kinase-2 for the Treatment of
Cholangiocarcinoma (CCA)'[1], was authored by scientists from the Mayo
Clinic, Apogee Biotechnology Corp. (Apogee), the Medical University of
South Carolina (MUSC) and RedHill. It will be presented by one of its
authors, Dr. Lewis R. Roberts, M.B., Ch.B., Ph.D, a gastroenterologist and
hepatologist at Mayo Clinic and the External Co-Chair of The Cancer Genome
Atlas (TCGA) Cholangiocarcinoma Project of the National Cancer Institute